Prosecution Insights
Last updated: November 12, 2026
Application No. 18/724,230

CLOSED-LOOP CONTROL SYSTEM FOR PULSE ABLATION

Final Rejection §102§103
Filed
Jun 26, 2024
Priority
Dec 03, 2021 — CN 202111466101.4 +1 more
Examiner
GUERRERO ROSARIO, ANA VERUSKA
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Hangzhouready Biological Technology Co. Ltd.
OA Round
2 (Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
91%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
28 granted / 63 resolved
-25.6% vs TC avg
Strong +47% interview lift
Without
With
+46.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
39 currently pending
Career history
120
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The Amendments filed on August 20, 2026 have been entered. Applicant’s amendments have overcome the 112(b) rejection previously set-forth in the Non-Final Office Action mailed on 05/20/2026; however, the objection to the Specification continues to remain given that no updated Abstract has been received. Currently, claims 1, 5, and 7 have been amended, and claims 1-8 are pending in the application. Specification Applicant is reminded of the proper content of an abstract of the disclosure. A patent abstract is a concise statement of the technical disclosure of the patent and should include that which is new in the art to which the invention pertains. The abstract should not refer to purported merits or speculative applications of the invention and should not compare the invention with the prior art. If the patent is of a basic nature, the entire technical disclosure may be new in the art, and the abstract should be directed to the entire disclosure. If the patent is in the nature of an improvement in an old apparatus, process, product, or composition, the abstract should include the technical disclosure of the improvement. The abstract should also mention by way of example any preferred modifications or alternatives. Where applicable, the abstract should include the following: (1) if a machine or apparatus, its organization and operation; (2) if an article, its method of making; (3) if a chemical compound, its identity and use; (4) if a mixture, its ingredients; (5) if a process, the steps. Extensive mechanical and design details of an apparatus should not be included in the abstract. The abstract should be in narrative form and generally limited to a single paragraph within the range of 50 to 150 words in length. See MPEP § 608.01(b) for guidelines for the preparation of patent abstracts. The abstract of the disclosure is objected to because it exceeds 150 words and contains legal phraseology. A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-3 and 6-8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Xue (C.N. Application No. 112022331 B). Regarding independent claim 1, Xue discloses a closed-loop control system for pulse ablation, comprising an electric pulse host (1000) and an electrode group (2400, 2500) (page 5, lines 5-8 under “Detailed Description” & Fig. 1), the electrode group comprising a plurality of electrodes (i.e., group of electrodes comprising a detection electrode and an ablation electrode) (page 6, lines 24-27); the electric pulse host comprising a main control module (i.e., combination of a central control unit of a lower computer 1900’ and a control unit of an upper computer 1900) (page 3, lines 6-8, bottom-up; page 5 last paragraph – page 6 lines 1-8 and lines 13-14), a pulse transmission module (asymmetric pulse discharge circuit) (page 2, lines 2-5; page 6, lines 15-23), an electrophysiological signal sampling module (upper computer 1900), a first electrode control unit and a second electrode control unit (discharge switch elements comprising a bridge circuit made up of relays or switch tubes and four control drive units) (page 3, lines 17-21, bottom-up); the main control module being sequentially connected with the pulse transmission module, the first electrode control unit and the electrode group (see Figs. 1-2), the main control module controlling the pulse transmission module to output a pulse signal and selecting a specific electrode through the first electrode control unit to release the pulse signal (page 3, lines 14-16, bottom-up and lines 4-5, bottom-up); the main control module being sequentially connected with the electrophysiological signal sampling module, the second electrode control unit and the electrode group (see Figs. 1-2), the main control module selecting an electrode through the second electrode control unit and sampling an electrocardiogram signal through the electrophysiological signal sampling module (page 3, lines 6-8, bottom-up), the electrocardiogram signal referring to a potential amplitude signal (R wave) between the selected electrodes (page 6, lines 34-38); wherein one of the plurality of electrodes is selectively operable in a first mode to release the pulse signal for ablation and in a second mode to provide an electrical signal for sampling the electrocardiogram signal (in the configuration where the detection electrodes can be switched to the ablation electrodes; page 4, lines 16-17); the main control module determining a treatment progress (page 3, paragraph under “Disclosure of Invention”) according to the sampled electrocardiogram signal (page 6, lines 33-35, bottom-up) and adjusting the pulse signal output by the pulse transmission module in real time according to the treatment progress (page 3, lines 12-21, bottom-up; page 6, lines 24-27 and lines 31-33). Regarding claim 2, Xue discloses wherein the pulse transmission module and the electrophysiological signal sampling module work alternately and switch once every heartbeat cycle (page 3, last paragraph – page 4, lines 1-6). It is noted that the recitation of “the pulse transmission module and the electrophysiological signal sampling module work alternately and switch once every heartbeat cycle” is regarded as a functional recitation of the intended use of the closed-loop control system. It has been held that a functional recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In the instant case, the pulse transmission module of Xue readily provides for such functionality given that the system allows the user to readably adjust the discharge pulse signals to be outputted in specific cycles. Regarding claim 3, Xue discloses wherein the main control module achieves single-electrode pulse transmission control and single-electrode electrocardiograph signal sampling through the first electrode control unit and the second electrode control unit (page 4, lines 10-12). Regarding claim 6, Xue discloses wherein the main control module controls the pulse transmission module to release the pulse signal in an electrocardiogram refractory period according to the electrocardiogram signal (page 6, lines 34-38). Regarding claim 7, Xue discloses wherein the closed-loop control system for pulse ablation further comprises a man-machine interaction module (combination of the upper computer 1900 console, a display device, a foot switch, and input/output panel; page 6 line 9), the man-machine interaction module is connected with the main control module and configured to set parameters, and the parameters comprise a voltage amplitude and a pulse width of the pulse signal (page 6 lines 4-8 and lines 15-23). Regarding claim 8, Xue discloses wherein the pulse transmission module comprises a high-voltage power supply (1200) and a pulse generation circuit, and the pulse generation circuit achieves a bidirectional pulse by adopting a four-way switch module (page 3, lines 17-21, bottom-up; page 5, line 9 and lines 23-25 under “Detailed Description”). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 4 is rejected under 35 U.S.C. 103 as being unpatentable over Xue as applied to claim 1 above, and further in view of Gorzycki (U.S. Application No. 20210322086 A1). Regarding claim 4, Xue discloses the main control module determining a treatment progress according to the sampled electrocardiogram signal and adjusting the pulse signal output by the pulse transmission module in real time according to the treatment progress (page 6, lines 24-27 and lines 31-33). However, Xue does not disclose the detailed steps described in the rest of the claim. Gorzycki, in the same field of endeavor, teaches an ablation system comprising an ECG detector (30) comprising a set of ECG electrodes (pa. 0055 & Fig. 1), the system includes a controller (100) comprising a microcontroller or microprocessor adapted to execute programmable instructions (pa. 0056 & Fig. 2) and a triggering circuit (160) configured to receive, process, and analyze an ECG-type signal (pa. 0058). During a treatment regiment, a cardiac beat or cycle of the patient is analyzed in order to set a safe period used for delivery of therapy, the safe period being between the R-wave and the T-wave, wherein the analysis includes identifying/detecting features of the cardiac signal such as, for example, the QT interval at a given cardiac rate, measuring and recording QRS width, amplitude of any of the P, R, or T waves, shape of the P-wave or QRS complex, shape/elevation of the signal during the ST interval relative to a baseline, etc. (pa. 0074, 0080). In order to detect the features of the beat, a detection threshold is applied to the cardiac signal to detect the cardiac event (pa. 0081), wherein several methods may be employed to confirm beat detection using slew rate, width, and/or amplitude (pa. 0082-0084) (i.e., when performing first electrocardiograph signal sampling, if a sampled electrocardiograph signal A is greater than a first threshold, the main control module controlling the pulse transmission module to output a pulse signal according to a set voltage amplitude and pulse width). A second beat may then be sensed/detected, with confirmation of the beat taking place before the therapy is issued using the safe period settings previously defined by the first/previous beat. After therapy is issued, the process repeats for the future beats with an updated safe period set using those respective future beats (pa. 0080 Fig. 6) (i.e., for each subsequent electrocardiograph signal sampling, comparing a newly sampled electrocardiograph signal with a previously sampled electrocardiograph signal). Using the slew rate to confirm a beat, some patients have wide QRS complexes, and the use of width may be tailored to such patients by measuring R-wave or QRS width in advance to set a threshold use in a width analysis. It may be noted that the P-wave and R-wave may not be distinguished readily using width, and this issue can be addressed, for example, by configuring/adjusting the location of the surface QRS sensing electrodes in relatively lower positions relative to the heart (pa. 0083) (i.e., if the newly sampled electrocardiogram signal presents no change, indicating that the position of the corresponding electrode needs to be adjusted). Depending on the safe window/period duration, the burst to be delivered as ablation therapy can be adjusted. For example, a therapy burst can be issued as a series of square wave pulses each having a pulse width, separated by an interpulse interval, up to a set quantity of the pulses, and the duration of the pulses can be adjusted to fit within the safe period (pa. 0075) (i.e., if the newly sampled electrocardiogram signal presents a change, calculating a change amplitude and correspondingly adjusting waveform parameters of the pulse signal output by the pulse transmission module according to the change amplitude). Lastly, the detected events in the ECG signal may be passed through a confirmation routine, wherein if the detected event passes the confirmation routine, the beat is confirmed and therapy is delivered and the treatment ends, but if the detected event fails the confirmation routine, the ECG signal detection process continues (pa. 0094-0096) (i.e., when the newly sampled electrocardiogram signal reaches a set second threshold, ending an ablation process). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have added the ECG detector, the controller, and the triggering circuit of Gorzycki to the system taught by Xue for the purpose of allowing the main control module to determine the treatment progress according to the sampled electrocardiogram signal by more accurately and efficiently analyzing the ECG signals. Claim 5 is rejected under 35 U.S.C. 103 as being unpatentable over Xue as applied to claim 1 above, and further in view of Sano (W.O. Application No. 2020243461 A1). Regarding claim 5, Xue discloses wherein the closed-loop control system for pulse ablation further comprises a voltage (1600) and current sensor (1700) (page 5, lines 9-10, under “Detailed Description”). However, Xue does not disclose the voltage and current sensors are configured to monitor arc discharge caused by a position change between the electrodes, after the pulse signal is triggered, perform voltage and current sampling after a delay of certain time, nor by sampling in time smaller than a pulse width, transmit a sampling signal of the voltage and current sampling in real time to the main control module for analysis after analog-to-digital conversion, and perform arc determination by determining change characteristics of voltage and current. Sano, in the same field of endeavor, teaches an ablation system comprising an apparatus for preventing, mitigating, and/or reducing tissue damage during a pulsed electric field therapy comprising a plurality of electrical pulses. The system further comprises circuitry configured to detect an onset and/or occurrence of an electrical arc and dynamically modify a delivery profile of the electrical pulses responsive to the detection (pa. 0018). As seen in figures 2A-2C, graphs of current (112) measurements and voltage (111) measurements are used to determine electric arcing during pulsed electric field therapies, wherein the arcing events can be detected in real time by hardware and/or software and may be used to halt pulse delivery and/or modify the pulse delivery protocol to prevent and/or reduce the occurrence of electrical arcing during subsequent pulses (pa. 00108). Figures 3A-3C illustrate a method of preventing electrical arcing by dynamically modifying the pulse delivery profile. Referring to figure 3A, a pulse (Pulse n) of a plurality of electrical pulses of the pulsed electric field therapy may be identified as not having an electrical arc detected. Referring to figure 3B, a pulse (Pulse n+1) of the plurality of electrical pulses may be identified as having a component with a rapidly increasing current, and thus a potential future electrical arc may be identified. Referring to figure 3C, the delivery rate of an electrical pulse (Pulse n+2) may be modified responsive to detecting the potential electrical arc. When the potential electrical arc is identified, the time within the pulse at which that event occurred may be recorded. In some embodiments, the modification may include an alteration of a duration of the electrical pulse (e.g., a shortened duration) and/or an alteration of an amplitude of the electrical pulse (pa. 00109). In other words, after the pulse signal is triggered (starting in Pulse n), the ablation system is able to continuously sample the voltage and current after a delay of certain time, wherein the delay is defined as the time between the end of Pulse n and the end of Pulse n+1. Examiner notes that the claim language is broad and does not require the voltage and current sampling be conducted between pulses or not during a pulse. Furthermore, the voltage and the current sampling is conducted in a time smaller than the pulse width given that, as seen in figure 2C, the ablation system is able to detect and record a specific point in time where an arcing event has occurred, wherein that specific point in time is smaller than the total pulse width. After the sampling of the voltage and current signal is conducted, the ablation system transmits the signal to the circuitry for analysis after analog-to-digital conversion, and the system further modifies the pulse signal in real time (pa. 00121). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have added the arc detection circuitry and other hardware/software taught by Sano into the control system of Xue for the purpose of allowing the user to monitor, mitigating, and preventing future arcing events that may be harmful to the patient. Response to Arguments Applicant's arguments filed 08/20/2026 have been fully considered but they are not persuasive. With regards to newly amended independent claim 1, Applicant argues that the Xue reference does not disclose "wherein one of the plurality of electrodes is selectively operable in a first mode to release the pulse signal for ablation and in a second mode to provide an electrical signal for sampling the electrocardiogram signal". Specifically, Applicant contends that although Xue states that a detection electrode may be "switched to" an ablation electrode, Xue does not disclose that the same physical electrode is connected to both the pulse- transmission circuit and the detection circuit and is selectively operated for both functions. However, Examiner, respectfully, disagrees. The newly added claim language of claim 1 is broad and only requires that one of the electrodes is operable in a first mode to release the pulse signal for ablation and in a second mode to provide an electrical signal for sampling the electrocardiogram signal. The claim language of the apparatus claim 1 does not specify the physical/electrical connection of such electrode to both the pulse- transmission circuit and the detection circuit. For completeness sake, even if such amendment were to be made in the following round of prosecution, the Xue reference inherently teaches this concept. Xue discloses wherein the detection electrodes can be switched to the ablation electrodes (page 4, lines 16-17), thereby implicitly suggesting that in this configuration, at least one electrode of the plurality of electrodes may be electrically/physically connected to both the pulse- transmission circuit and the detection circuit in order to perform such functionalities. Therefore, the prior art meets the claim limitation, and the rejection is maintained. Additionally, with regards to claim 1, Applicant further argues that the Xue reference does not disclose nor suggest the claimed closed-loop relationship between the sampled electrocardiogram signal, the determined treatment progress, and real-time adjustment of the ablation pulse. Specifically, Applicant cites that Xue describes its detection electrode as collecting electrical stimulation signals to determine and feedback the ablation effect and process in real time. Applicant states that Xue does not disclose that the host determines treatment progress from those detected signals and then adjusts the pulse output based on the determined treatment progress, and although Xue discloses adjustable pulse parameters and control of the pulse-generation circuit, Applicant contends that such parameters are set as working parameters or controlled according to predetermined control signals. Finally, Applicant also contends that Xue does not disclose changing the pulse output in response to a change in the detected electrocardiogram signal or according to treatment progress determined from that signal. However, Examiner disagrees. The Xue reference discloses an irreversible electroporation ablation system, which comprises a host machine and an ablation device, wherein the host machine can generate high-voltage high-frequency alternating asymmetric pulses. The asymmetrical pulse is applied to the ablation electrode to enable the ablation electrode to output an electric stimulation signal. The detection electrode detects the electric stimulation signal output by the ablation electrode and feeds back the electric stimulation signal to the host. The host comprises an upper computer and a lower computer, wherein the upper computer receives the working parameters of the asymmetric pulse and transmits the working parameters to the lower computer. The lower computer then generates a control signal according to the working parameters and transmits the control signal to the asymmetric pulse discharge circuit which in turn generates corresponding high-voltage high-frequency alternating asymmetric pulses according to the working parameters (page 3, lines 18-28), wherein the high-voltage high-frequency alternating asymmetric pulses have adjustable pulse width, adjustable duty ratio, and adjustable positive and negative polarities (page 3, lines 43-44), and wherein the discharge pulse of the asymmetric pulse discharge circuit is set to continuously adjust the pulse width of the positive pulse and the negative pulse (page 4, lines 4-7). Therefore, the Xue reference does contemplate adjusting the pulse output in response to a change in the detected electrocardiogram signal or according to treatment progress given that is it able to continuously adjust the working parameters to ensure optimal treatment. Therefore, for the reasonings set-forth above, the rejection using the Xue reference is maintained. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Ben-David (US 7778711 B2) teaches an electrode device, adapted to be coupled to a tissue of a subject, and a control unit, adapted to drive the electrode device to apply a current to the tissue. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANA VERUSKA GUERRERO ROSARIO whose telephone number is (571)272-6976. The examiner can normally be reached Monday - Thursday 7:00 - 4:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.V.G./Examiner, Art Unit 3794 /Ronald Hupczey, Jr./Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Jun 26, 2024
Application Filed
May 20, 2026
Non-Final Rejection mailed — §102, §103
Aug 20, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758152
Contact Quality System and Method
4y 9m to grant Granted Oct 13, 2026
Patent 12721535
PULSE TRANSIT TIME MEASUREMENT DEVICE AND BLOOD PRESSURE MEASUREMENT DEVICE
5y 6m to grant Granted Sep 01, 2026
Patent 12667415
BASKET CATHETER WITH CLOVERLEAF STRUCTURE TO PROVIDE PREDETERMINED LATERAL STIFFNESS AND AXIAL STRAIN
3y 3m to grant Granted Jun 30, 2026
Patent 12642574
MEDICAL INSTRUMENT CUTTING SYSTEMS AND METHODS
5y 1m to grant Granted Jun 02, 2026
Patent 12622738
MEDICAL DEVICES AND RELATED METHODS
4y 11m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
91%
With Interview (+46.7%)
Moderate
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month